The Shotlee Journal
Browse Shotlee articles about Health & Wellness.
Showing 9 / 258 Health & Wellness articles
New research from Stanford Medicine reveals a potential solution to the muscle loss associated with GLP-1 medications like Ozempic and Wegovy, offering hope for stronger, healthier weight loss.
The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
A recent national database study reveals significant obstetric risks associated with semaglutide exposure before and during pregnancy, highlighting the importance of the weight rebound effect.
Discover how GLP-1 medications, known for weight loss, may also significantly reduce the need for knee replacement surgery. This article delves into the latest research and its implications for joint health.
A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.
